TPST-1120
As of the edition of 20 October 2026, TPST-1120 is a drug known only by a code name: in active development; acts on PPARA.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2027
- Kind
- Code name only
- Registered trials
- 3, 0 stopped early
- Disease areas
- Cancer; Digestive system; Hormones; Lungs and airways; Pregnancy and women's health; Skin and connective tissue
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| PPARA | Peroxisome proliferator-activated receptor alpha | Q07869 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 1 | 1 | 0 | 0 |
| Phase 2 | 1 | 0 | 1 | 0 |
| Phase 3 | 1 | 0 | 1 | 0 |
| All trials | 3 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Tempest Therapeutics | Lead sponsor of trials | 2019 to now |
| Roche | Lead sponsor of trials | 2020 to now |